Abstract
Drug adverse effects (ADEs) and toxicities have been extensively studied from chemical structure, genetic, biological systems and clinical perspectives. The rapid accumulation of chemical, biological and clinical data are highly useful for characterizing and predicting ADEs, and have enabled increasing exploration of computational methods as low cost tools for predicting various ADEs and toxicities. This article reviews the strategies, current progresses, underlying difficulties and future prospects in using computational methods for predicting ADEs and toxicities.
Keywords: Adverse drug effects, adverse drug reaction, drug discovery, drug testing, pharmaceutical, side effect, toxicity, toxicology, risk assessment
Current Drug Safety
Title:In Silico Prediction of Adverse Drug Reactions and Toxicities Based on Structural, Biological and Clinical Data
Volume: 7 Issue: 3
Author(s): Xin Liu, Zhe Shi, Ying Xue, Ze Rong Li, Sheng Yong Yang, Yu Quan Wei and Yu Zong Chen
Affiliation:
Keywords: Adverse drug effects, adverse drug reaction, drug discovery, drug testing, pharmaceutical, side effect, toxicity, toxicology, risk assessment
Abstract: Drug adverse effects (ADEs) and toxicities have been extensively studied from chemical structure, genetic, biological systems and clinical perspectives. The rapid accumulation of chemical, biological and clinical data are highly useful for characterizing and predicting ADEs, and have enabled increasing exploration of computational methods as low cost tools for predicting various ADEs and toxicities. This article reviews the strategies, current progresses, underlying difficulties and future prospects in using computational methods for predicting ADEs and toxicities.
Export Options
About this article
Cite this article as:
Liu Xin, Shi Zhe, Xue Ying, Rong Li Ze, Yong Yang Sheng, Quan Wei Yu and Zong Chen Yu, In Silico Prediction of Adverse Drug Reactions and Toxicities Based on Structural, Biological and Clinical Data, Current Drug Safety 2012; 7(3) . https://dx.doi.org/10.2174/157488612803251351
DOI https://dx.doi.org/10.2174/157488612803251351 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
New Cathepsin D Inhibitorswith Hydroxyethylamine Isosteres: Preparation and Characterization
Medicinal Chemistry Targeting the Most Upstream Site of Wnt Signaling Pathway Provides a Strategic Advantage for Therapy in Colorectal Cancer
Current Drug Targets The Epigenetic Modification of Epigallocatechin Gallate (EGCG) on Cancer
Current Drug Targets Evolutionary Significance of Iodine
Current Chemical Biology Overcoming the Hurdles of Tumor Immunity by Targeting Regulatory Pathways in Innate and Adaptive Immune Cells
Current Pharmaceutical Design Targeting Protein Kinase Inhibitors with Traditional Chinese Medicine
Current Drug Targets Analytical Techniques for DNA Methylation – An Overview
Current Pharmaceutical Analysis Targeting Prostate Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Vitamin D Receptor Signaling and Pancreatic Cancer Cell EMT
Current Pharmaceutical Design Cannabinoid 1 (CB1) Receptor - Pharmacology, Role in Pain and Recent Developments in Emerging CB1 Agonists
CNS & Neurological Disorders - Drug Targets The Expression, Function and Targeting of Haem Oxygenase-1 in Cancer
Current Cancer Drug Targets Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020)
Current Medicinal Chemistry Imaging of Spinal Bone Tumors: Principles and Practice
Current Medical Imaging Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin
Current Cancer Drug Targets The Prognosis of Patients with Liver Metastases from Colorectal Cancer still Depends on Anatomical Presentation more than on Treatments
Current Cancer Drug Targets MiRNAs in Human Cancers: The Diagnostic and Therapeutic Implications
Current Pharmaceutical Design Monitoring T Cell Responses to Cancer Immunotherapy: Can We Now Identify Biomarkers Predicting Patients Who will be Responders
Current Cancer Therapy Reviews Reconstruction, Topological and Gene Ontology Enrichment Analysis of Cancerous Gene Regulatory Network Modules
Current Bioinformatics Pharmacogenetic Aspects of Drug Metabolizing Enzymes in Busulfan Based Conditioning Prior to Allogenic Hematopoietic Stem Cell Transplantation in Children
Current Drug Metabolism Fighting Fire with Fire: A Patent for the Combined Application of Oncolytic Herpes Viruses and Antiangiogenic Agents in the Battle Against Human Cancers
Recent Patents on Anti-Cancer Drug Discovery